New therapies for castrate-resistant prostate cancer

被引：3

作者：

Williams, Stephen B. ^{[1
]}

Lay, Aaron H. ^{[1
]}

Lau, Clayton S. ^{[2
]}

Josephson, David Y. ^{[2
]}

Wilson, Timothy G. ^{[2
]}

Choueiri, Toni K. ^{[3
]}

Pal, Sumanta K. ^{[4
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Div Urol, Sch Med, Boston, MA 02115 USA

[2] City Hope Comprehens Canc Ctr, Div Urol Oncol, Dept Urol, Duarte, CA 91010 USA

[3] Harvard Univ, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA

[4] City Hope Comprehens Canc Ctr, Div Genitourinary Malignancies, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 13期

关键词：

castrate resistant; chemotherapy; outcomes; prostate cancer; review; MITOXANTRONE PLUS PREDNISONE; I CLINICAL-TRIAL; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; DOCETAXEL; CYP17; INHIBITOR; IMMUNOTHERAPY; ANTIANDROGEN; CHEMOTHERAPY;

D O I：

10.1517/14656566.2011.590133

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

引用

页码：2069 / 2074

页数：6

共 50 条

[1] Therapies in development for castrate-resistant prostate cancer
Harzstark, Andrea L.
Ryan, Charles J.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (02) : 259 - 268
[2] Emerging therapies in castrate-resistant prostate cancer
Lassi, Kiran
Dawson, Nancy A.
[J]. CURRENT OPINION IN ONCOLOGY, 2009, 21 (03) : 260 - 265
[3] Emerging therapies in castrate-resistant prostate cancer
Zarour L.
Alumkal J.
[J]. Current Urology Reports, 2010, 11 (3) : 152 - 158
[4] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
Dayyani, Farshid
Gallick, Gary E.
Logothetis, Christopher J.
Corn, Paul G.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) : 1665 - 1675
[5] New developments in castrate-resistant prostate cancer
Shore, N.
Mason, M.
de Reijke, Th. M.
[J]. BJU INTERNATIONAL, 2012, 109 : 22 - 32
[6] Emerging novel therapies in the treatment of castrate-resistant prostate cancer
Abdulla, Alym
Kapoor, Anil
[J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (02): : 120 - 133
[7] Re: Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
Sartor, Oliver
Parker, Chris
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (09) : 717 - 717
[8] New Therapeutics to Treat Castrate-Resistant Prostate Cancer
Acar, Omer
Esen, Tarik
Lack, Nathan A.
[J]. SCIENTIFIC WORLD JOURNAL, 2013,
[9] New horizons in the management of castrate-resistant prostate cancer
Kamel, Mohamed H.
Raheem, Omer A.
Davis, Rodney
[J]. JOURNAL OF CLINICAL UROLOGY, 2018, 11 (04) : 258 - 265
[10] Castrate-Resistant Prostate Cancer Foreword
Taneja, Samir S.
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : XIII - XIII

← 1 2 3 4 5 →